Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a pioneering clinical trial for a cancer vaccine that targets a highly aggressive brain tumor found in young adults and adolescents. The vaccine, developed at UCLA, aims to activate the patient's dendritic cells to target genetic mutations in these tumors, potentially improving survival rates and advancing our understanding of the immune system's response to primary brain cancers. Funded by grants from the Department of Defense and the National Institutes of Health, this novel approach offers hope for treating this challenging form of pediatric brain cancer and may lead to a new standard of care in the future.



















